Randall K. Johnson

Nessuna posizione attualmente

77 anni

Health Technology

Profilo

Randall K.
Johnson worked as an Independent Director at Callisto Pharmaceuticals, Inc. from 2005 to 2013.
Prior to that, he was the Group Director of the Oncology Research Department at GSK Plc from 1982 to 2002.
He also held the same position at Smithkline Beecham Pharmaceuticals (Canada).

Precedenti posizioni note di Randall K. Johnson

Società	Posizione	Fine
Callisto Pharmaceuticals, Inc. Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY.	Direttore/Membro del Consiglio	22/01/2013
GSK PLC	Corporate Officer/Principal	01/02/2002
Smithkline Beecham Pharmaceuticals (Canada)	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Randall K. Johnson

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Randall K. Johnson

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
GSK PLC	Health Technology

Aziende private	2
Callisto Pharmaceuticals, Inc. Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY.	Health Technology
Smithkline Beecham Pharmaceuticals (Canada)